Pharmaceuticals News and Research

RSS

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Pharmaceutical scientists at the University of Sunderland have been awarded £125,000 by the Cystinosis Foundation (CF) UK to fund the next stage of their research into a rare genetic disease.

7 Mar 2013

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags.

6 Mar 2013

FDA accepts AMAG’s Feraheme sNDA for review

AMAG Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012.

6 Mar 2013

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

Researchers have identified a critical protein role in the metastasis of melanoma, the most serious form of skin cancer.

6 Mar 2013

Two asthma medications combined in one inhaler more effective than recommended treatment

Two large randomised trials published to coincide with the launch of The Lancet Respiratory Medicine provide compelling new evidence that using two types of common asthma medications combined in one inhaler for both preventive and rescue treatment (Single inhaler Maintenance and Reliever Therapy; SMART) is more effective at reducing attacks than guideline-based treatment in adults whose asthma is not well controlled, and is safe and well tolerated.

5 Mar 2013

Continuous dyskinesia monitoring technology for Parkinson’s to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies (GLNT) announced today that they are launching commercialization and clinical studies to validate a system for objective, continuous monitoring of dyskinesias associated with Parkinson’s disease.

5 Mar 2013

Sanofi, DBV Technologies partner to produce Viaskin's Active Pharmaceutical Ingredients

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergies, announced today that it entered into a strategic manufacturing agreement with Sanofi to produce Viaskin's Active Pharmaceutical Ingredients (API), such as the peanut protein extract.

5 Mar 2013

Sanford-Burnham enters into partnership to test furin for treatment of dengue fever

Sanford-Burnham Medical Research Institute and 60- Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics.

5 Mar 2013

World Trade Organization meeting this week to discuss proposed extension of TRIPS transition period for LDCs

"On March 5-6, the Trade-Related Aspects of Intellectual Property Rights Council of the World Trade Organization will meet in Geneva to seal the fate of the proposal lengthening the TRIPS transition period for the 49 least-developed countries [LDCs]," Devex's "The Development Newswire" reports, noting, "The transition period, set to expire July 2013, exempts LDCs from the terms of the TRIPS agreement on patents and test data protection for pharmaceuticals."

5 Mar 2013

Eisai, DSM sign 3 year master supply agreement for production of sterile products

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products.

5 Mar 2013

Médecins Sans Frontières’ concerns over TPP negotiations

As closed-door talks for the Trans-Pacific Partnership (TPP) Agreement resume in Singapore this week, international medical humanitarian organisation Médecins Sans Frontières is calling on Australia and negotiating countries to reject rules that threaten to dismantle internationally agreed public health safeguards and restrict access to medicines in developing countries.

4 Mar 2013

BioClinica, CPI and Medtentia partner for eClinical and Imaging Core Lab solutions

BioClinica, Inc., a global provider of clinical trial management solutions, today announced an agreement for BioClinica Express EDC, data management, and imaging core lab services with Finnish company Medtentia International, in partnership with the contract research organization (CRO) clinicalprojects international (CPI).

From Clario 4 Mar 2013

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.

4 Mar 2013

DBV Technologies total revenues increase to €2,776,588 for full year 2012

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March 1st, 2013.

4 Mar 2013

Aquasana to introduce two filtration products at International Home + Housewares Show

Aquasana will make a splash at the International Home + Housewares Show in Chicago March 2-5 with the introduction of two groundbreaking filtration products. Both represent industry leadership for chloramine contamination reduction.

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Report: Drug companies spent $84M marketing pharmaceuticals in the District of Columbia in 2011

Drug companies spent nearly $84 million marketing pharmaceuticals in the District of Columbia in 2011, including an outlay of nearly $19 million for gifts given to physicians, hospitals and other health care providers, according to a report by researchers at the George Washington University School of Public Health and Health Services.

2 Mar 2013

State roundup: Medicaid costs slow states' recovery

Like a bad hangover that won't go away, some states are still suffering from the effects of the recession that technically ended three and half years ago. … Some states, including Iowa, Indiana and Tennessee, started the new session with surpluses, but none are planning to embark on new spending.

1 Mar 2013

GlaxoSmithKline's HIV/AIDS business joins Medicines Patent Pool

"GlaxoSmithKline's HIV/AIDS drugs business is to share intellectual property rights on children's medicine in a patent pool designed to make treatments more widely available in poor countries," Reuters reports.

1 Mar 2013

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).

1 Mar 2013

Pharmaceuticals News and Research

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

FDA accepts AMAG’s Feraheme sNDA for review

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

Two asthma medications combined in one inhaler more effective than recommended treatment

Continuous dyskinesia monitoring technology for Parkinson’s to be developed by Great Lakes NeuroTechnologies

Sanofi, DBV Technologies partner to produce Viaskin's Active Pharmaceutical Ingredients

Sanford-Burnham enters into partnership to test furin for treatment of dengue fever

World Trade Organization meeting this week to discuss proposed extension of TRIPS transition period for LDCs

Eisai, DSM sign 3 year master supply agreement for production of sterile products

Médecins Sans Frontières’ concerns over TPP negotiations

BioClinica, CPI and Medtentia partner for eClinical and Imaging Core Lab solutions

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

DBV Technologies total revenues increase to €2,776,588 for full year 2012

Aquasana to introduce two filtration products at International Home + Housewares Show

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Report: Drug companies spent $84M marketing pharmaceuticals in the District of Columbia in 2011

State roundup: Medicaid costs slow states' recovery

GlaxoSmithKline's HIV/AIDS business joins Medicines Patent Pool

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence